Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech
CompanyDeals

Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech

US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security
CompanyDrug

US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security

Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech
Company

Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech

BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study
CompanyDrug

BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study

Beijing Wantai Launches Phase III Trial for 9-Valent HPV Vaccine in Chinese Males
CompanyDrug

Beijing Wantai Launches Phase III Trial for 9-Valent HPV Vaccine in Chinese Males

Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA₂ Inhibitor for Alzheimer's Disease
CompanyDrug

Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA₂ Inhibitor for Alzheimer’s Disease

Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors

Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case
CompanyDrug

Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case

Roche's Columvi Approved by EC for Relapsed DLBCL Treatment in Europe
CompanyDrug

Roche’s Columvi Approved by EC for Relapsed DLBCL Treatment in Europe

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-1819 in Allergic Rhinitis Study
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-1819 in Allergic Rhinitis Study

CSPC Pharmaceutical Gains FDA Approval for SYS6041 ADC in Advanced Solid Tumors
CompanyDrug

CSPC Pharmaceutical Gains FDA Approval for SYS6041 ADC in Advanced Solid Tumors

Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases
CompanyDeals

Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases